Neurocrine Reports Q4 Earnings

Biopharmaceutical company posts revenue of $805.5 million, beating Wall Street expectations

Published on Feb. 11, 2026

Got story updates? Submit your updates here. ›

Neurocrine Biosciences Inc., a San Diego-based biopharmaceutical company, reported fourth-quarter earnings of $153.7 million, or $1.48 per share. While the results fell short of Wall Street expectations, the company posted revenue of $805.5 million in the period, beating analyst forecasts.

Why it matters

Neurocrine is a major player in the biopharmaceutical industry, and its quarterly earnings and revenue performance are closely watched by investors and analysts as indicators of the company's financial health and growth potential.

The details

The company's adjusted earnings per share of $1.88 fell short of the average analyst estimate of $2.25 per share. However, Neurocrine's revenue of $805.5 million in the fourth quarter beat the $782.9 million expected by analysts surveyed by Zacks. For the full year, the company reported a profit of $478.6 million, or $4.67 per share, on revenue of $2.86 billion.

  • Neurocrine reported its fourth-quarter earnings on February 11, 2026.

The players

Neurocrine Biosciences Inc.

A San Diego-based biopharmaceutical company that develops and commercializes therapies for neurological and endocrine-related disorders.

Got photos? Submit your photos here. ›

The takeaway

Neurocrine's fourth-quarter financial results demonstrate the company's ability to generate strong revenue, though its earnings fell short of Wall Street expectations. As a leading player in the biopharmaceutical industry, Neurocrine's performance is closely watched by investors and analysts as an indicator of the company's overall health and growth prospects.